TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07387068: First-in-human, Open-label, Phase 1 Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Select Advanced Malignant Solid Tumors

Sponsor: Genmab · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 121 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$6,785,856

Rescue Site Savings

+$4,492,488

Unlock Full NCT07387068 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07387068 Rescue Dossier →